Compare BioNTech SE - ADR (BNTX) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs State Street Real Estate Select Sector SPDR ETF — how do they compare? BioNTech SE - ADR trades at $91.37 (market cap $22.86B), while State Street Real Estate Select Sector SPDR ETF trades at $44.57. The key difference: State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | XLRE | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Sector/Thematic |
52-Week High | $119.34 | $45.36 |
52-Week Low | $83.89 | $40.01 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
XLRE, the Real Estate Select Sector SPDR ETF, trades at $44.70 with a 0.56% daily gain, reflecting positive momentum amid a broader real estate sector recovery. Technical indicators show a bullish moving average consensus while oscillators remain neutral. The ETF's low 0.08% expense ratio and 3.4% dividend yield provide cost-efficient real estate exposure. Recent news highlights REITs defying rate pressures with strong 2026 performance, though inflation and Treasury yield volatility remain headwinds.
The outlook for XLRE appears cautiously optimistic as real estate fundamentals improve with steady NOI growth and declining supply. Key opportunities include attractive valuations and potential rate stability, while risks center on interest rate sensitivity and economic slowdowns. With technical strength and sector tailwinds, XLRE offers diversified real estate exposure but requires monitoring of Federal Reserve policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
